Co-Entrapment of Sorafenib and Cisplatin Drugs and iRGD Tumour Homing Peptide by Poly[&epsilon;-caprolactone-co-(12-hydroxystearate)] Copolymer

Kántor, Izolda; Dreavă, Diana; Todea, Anamaria; Péter, Francisc; May, Zoltán; Biró, Emese; Babos, György; Feczkó, Tivadar

doi:10.3390/biomedicines10010043

Submit to this Journal Review for this Journal Edit a Special Issue

Article Menu

...

Open AccessArticle

Co-Entrapment of Sorafenib and Cisplatin Drugs and iRGD Tumour Homing Peptide by Poly[ε-caprolactone-co-(12-hydroxystearate)] Copolymer

^1,2,

³,

^3,*

^3,4

¹,

^1,3,

^1,2

and

Tivadar Feczkó

^1,2,*

Institute of Materials and Environmental Chemistry, Research Centre for Natural Sciences, Magyar Tudósok Körútja 2, H-1117 Budapest, Hungary

Research Institute of Biomolecular and Chemical Engineering, Faculty of Engineering, University of Pannonia, Egyetem u. 10, H-8200 Veszprém, Hungary

Faculty of Industrial Chemistry and Environmental Engineering, University Politehnica Timişoara, Carol Telbisz 6, RO-300001 Timişoara, Romania

⁴

Research Institute for Renewable Energies, University Politehnica Timișoara, G. Muzicescu 138, RO-300501 Timișoara, Romania

Authors to whom correspondence should be addressed.

Academic Editors: Shaker A. Mousa, Veronique Baud, Ciro Isidoro, Jacek M. Kwiecien, Masaru Tanaka, Muhammad Hanif, Ujendra Kumar, Alexander M. Seifalian, Zong Sheng Guo, David L. Bartlett and Allan Stensballe

Biomedicines 2022, 10(1), 43; https://doi.org/10.3390/biomedicines10010043

Received: 17 November 2021 / Revised: 13 December 2021 / Accepted: 22 December 2021 / Published: 26 December 2021

(This article belongs to the Special Issue Selected Papers in the 1st International Electronic Conference on Biomedicine (ECB 2021))

View Full-Text Download PDF

Browse Figures

Citation Export

Abstract

The drug-loaded nanocarriers have overcome various challenges compared with the pure chemotherapeutic drug, such as limited bioavailability, multiple drug resistance, poor patient compliance, and adverse drug reactions, offering advantages such as protection from degradation in the blood stream, better drug solubility, and improved drug stability. One promising group of controlled and targeted drug delivery systems is polymer-based nanoparticles that can sustain the release of the active agent by diffusion and their degradation. Sorafenib is the only drug that can prolong the life of patients suffering from hepatocellular carcinoma. Cisplatin remains one of the most widely used broad-spectrum anticancer drugs for the treatment of a variety of solid tumours. Nanoformulations can exert a synergistic effect by entrapping two drugs with different modes of action, such as sorafenib and cisplatin. In our study, polymeric nanoparticles were prepared with a good production yield by an improved double emulsion solvent evaporation method using the copolymer of 12-hydroxystearic acid with ε-caprolactone (12CL), a biocatalytically synthesised biocompatible and biodegradable carrier, for the co-entrapment of sorafenib and cisplatin in nanotherapeutics. A bovine serum albumin (BSA) model compound was used to increase the cisplatin incorporation; then, it was successfully substituted by a iRGD tumour penetrating peptide that might provide a targeting function of the nanoparticles. View Full-Text

Keywords: polymeric nanoparticles; drug encapsulation; biobased oligomers; sorafenib; cisplatin

▼ Show Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Supplementary Material

Supplementary File 1:
ZIP-Document (ZIP, 228 KiB)

Share and Cite

MDPI and ACS Style

Kántor, I.; Dreavă, D.; Todea, A.; Péter, F.; May, Z.; Biró, E.; Babos, G.; Feczkó, T. Co-Entrapment of Sorafenib and Cisplatin Drugs and iRGD Tumour Homing Peptide by Poly[ε-caprolactone-co-(12-hydroxystearate)] Copolymer. Biomedicines 2022, 10, 43. https://doi.org/10.3390/biomedicines10010043

AMA Style

Kántor I, Dreavă D, Todea A, Péter F, May Z, Biró E, Babos G, Feczkó T. Co-Entrapment of Sorafenib and Cisplatin Drugs and iRGD Tumour Homing Peptide by Poly[ε-caprolactone-co-(12-hydroxystearate)] Copolymer. Biomedicines. 2022; 10(1):43. https://doi.org/10.3390/biomedicines10010043

Chicago/Turabian Style

Kántor, Izolda, Diana Dreavă, Anamaria Todea, Francisc Péter, Zoltán May, Emese Biró, György Babos, and Tivadar Feczkó. 2022. "Co-Entrapment of Sorafenib and Cisplatin Drugs and iRGD Tumour Homing Peptide by Poly[ε-caprolactone-co-(12-hydroxystearate)] Copolymer" Biomedicines 10, no. 1: 43. https://doi.org/10.3390/biomedicines10010043

Find Other Styles

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Abstract views Pdf views Html views

Article Menu

Co-Entrapment of Sorafenib and Cisplatin Drugs and iRGD Tumour Homing Peptide by Poly[ε-caprolactone-co-(12-hydroxystearate)] Copolymer

Abstract

Supplementary Material

Share and Cite

Article Metrics

Article Access Statistics

Article Access Map by Country/Region

Further Information

Guidelines

MDPI Initiatives

Follow MDPI